Sprache auswählen
Coagulation factor X
Coagulation factor X Molekülinformation
| Englischer Name | Coagulation factor X | Anzahl der inverkehr gebrachten Arzneimittel | 112 |
| Anzahl der klinischen Arzneimittel | 48 | Target-Alias | EC 3.4.21，EC:3.4.21.6，Stuart factor，Coagulation factor X，F10，Stuart-Prower Factor，Prothrombinase，EC 3.4.21.6，Factor Xa，Factor X，FXA，FX |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Coagulation factor X |
| Target-Alias | EC 3.4.21，EC:3.4.21.6，Stuart factor，Coagulation factor X，F10，Stuart-Prower Factor，Prothrombinase，EC 3.4.21.6，Factor Xa，Factor X，FXA，FX |
| Anzahl der inverkehr gebrachten Arzneimittel | 112 |
| Anzahl der klinischen Arzneimittel | 48 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
Produktanfrage
Coagulation factor X Molekülalias
Coagulation factor X,F10,factor 10,factor X,Stuart Factor,Stuart-Prower factor
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Mim-8 | NN 7769; Mim8; Mim-8; NNC0365-3769; NN7769; NN-7769; NNC0365-3769 A; NN0365-3769 | Phase 3 Clinical | Novo Nordisk A/S | Hemophilia A | Details |
| Recombinant factor VIII (Saman daroo 8) | Phase 3 Clinical | Saman Daroo 8 | Hemophilia A | Details | |
| bemiltenase alfa | STSP-0601 | Phase 3 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Hemorrhagic Disorders; Hemophilia A; Hemophilia B; Hemorrhage; Blood Loss, Surgical | Details |
| Human coagulation factor VIII (Jiangxi Boya Bio-pharmaceutical) | Phase 3 Clinical | Boya Bio-Pharmaceutical Group Co Ltd | Hemophilia A | Details | |
| PEG-Recombinant FVIII-Fc fusion protein (Furen Medicines) | FRSW-117 | Phase 3 Clinical | Kaifeng Pharmaceutical (Group) Co Ltd | Blood Coagulation Disorders; Hemophilia A | Details |
| Recombinant Human Coagulation Factor VIII(Nanjing Shunxin Pharmaceuticals) | Phase 3 Clinical | Hemophilia A | Details | ||
| Human Antithrombin III(Sichuan Yuanda Shuyang Pharma) | Phase 3 Clinical | Yuanda Shuyang Life Sciences (Chengdu) Co Ltd | Thromboembolism; Antithrombin III Deficiency | Details | |
| Factor IX (Chengdu Rongsheng) | Phase 3 Clinical | Chengdu Rongsheng Pharmaceuticals Co Ltd | Hemophilia B; Hemorrhage | Details | |
| Eptacog Alfa Biosimilar(Aryogen Pharmed) | Phase 3 Clinical | Aryogen Pharmed Co | Hemophilia A; Factor VII Deficiency | Details | |
| Human prothrombin complex(Sinopharm Guizhou Plasma) | Phase 3 Clinical | Sinopharm Group Guizhou Bio-pharmaceutical Co Ltd | Hemophilia B; Hemorrhage | Details | |
| Factor IX (Hualan Biological Engineering) | Phase 3 Clinical | Hualan Biological Engineering Inc | Hemophilia B | Details | |
| Factor IX (Guangdong Shuanglin Bio-Pharmaceutical) | Phase 3 Clinical | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Hemophilia B | Details | |
| CT-001 (Coagulant Therapeutics) | CT-001; CT001 | Phase 3 Clinical | Coagulant Therapeutics Corp | Pain; Postpartum Hemorrhage | Details |
| Ketamine/sufentanil nasal spray (Cessatech) | CT-001 (Cessatech); CT-001 | Phase 3 Clinical | Cessatech A/S | Anesthesia; Pain; Hemorrhage | Details |
| Recombinant Human Coagulation Factor Ⅷ (Zhuangya Biotechnology) | Phase 3 Clinical | Zhuangya (Beijing) Biotechnology Co Ltd | Hemophilia A | Details | |
| Human prothrombin complex concentrate (Sichuan Yuanda Shuyang Pharmaceutical) | Phase 3 Clinical | Yuanda Shuyang Life Sciences (Chengdu) Co Ltd | Blood Coagulation Disorders | Details | |
| Dimolegin | DD-217 | Phase 3 Clinical | Pharmadiall Ltd | Venous Thromboembolism; Coronavirus Disease 2019 (COVID-19) | Details |
| Human coagulation factor Ⅷ /Human von Willebrand factor (Shandong Taibang Biological Products) | Phase 3 Clinical | Shandong Taibang Biological Products Co Ltd | von Willebrand Diseases; Hemophilia A; von Willebrand Disease, Type 1; Acquired hemophilia | Details | |
| Human prothrombin complex concentrate (Harbin Shiheng Bioengineering Pharmaceutical) | Phase 3 Clinical | Harbin Pacific Biopharmaceutical Co Ltd | Hemophilia B | Details | |
| Recombinant human coagulation factor VIII-Fc fusion protein(Haimen Gensciences) | FRSW-107 | Phase 3 Clinical | Jiangsu Gensciences lnc | Blood Coagulation Disorders; Coagulation Protein Disorders; Hemophilia A; Hemorrhage; Blood Loss, Surgical | Details |
| Human prothrombin complex(Sichuan Yuanda Shuyang Pharmceutical) | Phase 3 Clinical | Yuanda Shuyang Life Sciences (Chengdu) Co Ltd | Hemophilia B; Hemorrhage | Details | |
| Human prothrombin complex(Hunan Ziguang Huhan Nanyue Pharmaceutical) | Phase 3 Clinical | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Hemophilia B | Details | |
| aPCC-emicizumab | Phase 3 Clinical | Emory University | Hemophilia A | Details | |
| Human coagulation factor Ⅷ (Chengdu Institute Of Biological Products) | Phase 3 Clinical | Chengdu Institute Of Biological Products Co Ltd | Hemophilia A | Details | |
| Ciraparantag | PER-977 | Phase 2 Clinical | Perosphere Inc | Hemorrhagic Disorders | Details |
| Zifaxaban | TY-602 | Phase 2 Clinical | Tianjin Remedy Research Institute | Pulmonary Embolism; Venous Thrombosis | Details |
| Factor VIIa-CTP | MOD-5014; MOD-5017; OPK88005 | Phase 2 Clinical | Opko Health Inc, Prolor Biotech | Hemophilia A; Blood Coagulation Disorders, Inherited; Hemophilia B | Details |
| Tearexaban | TRx1 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Stroke; Venous Thrombosis | Details |
| Recombinant human coagulation factor VIIa-Fc fusion protein(Jiangsu Gensciences) | SS109; SS-109 | Phase 2 Clinical | Jiangsu Gensciences lnc | Hemophilia A; Hemophilia B; Factor VII Deficiency | Details |
| NXT-007 | NXT-007; RG-6512; RO-7589655 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd | Hemophilia A | Details |
| R-1663 | R-1663 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Thrombosis | Details |
| SAR-107375-E | SAR-107375-E; SAR-107375E | Phase 1 Clinical | Sanofi | Venous Thrombosis | Details |
| Eptacog alfa biosimilar (Valin Technologies) | Phase 1 Clinical | Valin Technologies | Hemophilia A | Details | |
| Marzeptacog alfa | CB-813; CB-813d; PF-5280602; PF-05280602 | Phase 1 Clinical | Catalyst | Hemophilia A; Hemophilia B | Details |
| Renaparin | Phase 1 Clinical | Vedanta Biosciences Inc | Delayed Graft Function | Details | |
| WA1-089 | WA1-089 | Phase 1 Clinical | North China Pharmaceutical Company Ltd | Venous Thromboembolism | Details |
| SYHA136 | SYHA-136 | Phase 1 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Venous Thromboembolism; Venous Thrombosis | Details |
| NNC0442-0344 A | NNC0442-0344 A; Inno8; NN7442 | Phase 1 Clinical | Novo Nordisk A/S | Hemophilia A | Details |
| Human prothrombin complex (National Drug Group Wuhan Blood) | Phase 1 Clinical | Sinopharm Wuhan Biopharmaceutical Co Ltd | Hemorrhage | Details | |
| Recombinant FVIII-Fc fusion protein (Chengdu Rongsheng) | Phase 1 Clinical | Chengdu Rongsheng Pharmaceuticals Co Ltd | Blood Coagulation Disorders; Hemophilia A | Details | |
| Rivaroxaban (Bio-synectics) | BS-112 | Phase 1 Clinical | Bio-Synectics Inc | Pulmonary Embolism; Venous Thrombosis | Details |
| Rivaroxaban (Austhera Biosciences) | AST-8294; DST-8294; KRIVA | Phase 1 Clinical | Dispersol Technologies Llc | Antiphospholipid Syndrome | Details |
| Fucosylated glycosaminoglycan sodium | Phase 1 Clinical | Mudanjiang Youbo Pharmaceutical Co Ltd | Venous Thrombosis | Details | |
| Human coagulation factor Ⅷ (Guizhou Taibang Biological Products) | Phase 1 Clinical | Guizhou Taibang Biological Products Co Ltd | Details | ||
| CKD-344 | CKD344; CKD-344 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Details | |
| Noxaban | Phase 1 Clinical | Zhaoke Pharmaceutical (Guangzhou) Co Ltd | Venous Thromboembolism; Liver Cirrhosis | Details | |
| HR-17020 | HR17020; HR-17020 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Venous Thromboembolism; Thromboembolism; Nephrotic Syndrome | Details |
| Enoxaparin sodium biosimilar (Pharmathen) | Pharmathen Sa | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Rurioctocog alfa | BLB-200; rAHF-PFM | Approved | 百因止, Advate | United States | Hemophilia A | null | 2003-07-25 | Hemophilia A | Details | |
| Enoxaparin Sodium | PRY-005; PK-10169; XRP-4563K; M-enoxaparin; RP-54563; RPY-005 | Approved | Sanofi | Klexane, 克赛, Lovenox, Clexane, Enoxamed | United States | Pulmonary Embolism; Venous Thrombosis | Sanofi-Aventis U.S. Llc | 1993-03-29 | Lung Neoplasms; Respiratory Distress Syndrome, Adult; Liver Diseases; Thromboembolism; Pre-Eclampsia; Coronary Disease; Coronavirus Infections; Fetal Growth Retardation; Cardiovascular Diseases; Venous Thrombosis; Hypoxia; Obstetric Labor, Premature; Nephrotic Syndrome; Thrombophilia; Intraoperative Complications; Postoperative Complications; Thrombosis; Carcinoma, Non-Small-Cell Lung; Catheter-Related Infections; Non-ST Elevated Myocardial Infarction; Brain Injuries, Traumatic; Ovarian Neoplasms; Myocardial Ischemia; Venous Thromboembolism; ST Elevation Myocardial Infarction; Myocardial Infarction; Esophageal Neoplasms; Stomach Neoplasms; Abdominal Neoplasms; Angina, Unstable; Pulmonary Embolism; Kidney Diseases; Colonic Neoplasms; Neoplasms; Coronavirus Disease 2019 (COVID-19); Obesity, Morbid; Pancreatic Neoplasms; Hip Fractures; Virus Diseases; Acute Coronary Syndrome | Details |
| Enoxaparin sodium biosimilar (Gland Pharma) | Approved | Gland Pharma Ltd | Cutenox | Angina, Unstable; Myocardial Infarction; Venous Thromboembolism; Venous Thrombosis | Gland Pharma | 2014-10-01 | Angina, Unstable; Myocardial Infarction; Venous Thromboembolism; Venous Thrombosis | Details | ||
| Human coagulation factor Ⅷ (Chengdu Rongsheng Pharmaceuticals) | Approved | Chengdu Rongsheng Pharmaceuticals Co Ltd | Mainland China | Hemophilia A | Chengdu Rongsheng Pharmaceuticals Co Ltd | 2001-01-01 | Hemophilia A | Details | ||
| Von Willebrand factor/coagulation factor VIII complex (human, Octapharma) | Approved | Octapharma | Wilate, Eqwilate, Wilnativ | Germany | Hemophilia A; von Willebrand Diseases | Octapharma | 2005-01-01 | von Willebrand Diseases; Hemophilia A | Details | |
| Human coagulation factor VIII (China Biologic Products) | Approved | Taibang Biotech (Shandong) Co Ltd | Mainland China | Hemophilia A | Taibang Biotech (Shandong) Co Ltd | 2012-06-15 | Hemophilia A; Hemorrhage; Blood Loss, Surgical | Details | ||
| Enoxaparin sodium biosimilar (Apotex Pty Ltd) | Approved | Apotex | Australia | Myocardial Ischemia; Angina, Unstable; Venous Thromboembolism; Thrombosis; Venous Thrombosis | Apotex | 2020-02-10 | Myocardial Ischemia; Angina, Unstable; Venous Thromboembolism; Venous Thrombosis; Thrombosis | Details | ||
| Anti-inhibitor coagulant complex (Baxalta) | Approved | Baxalta Incorporated | PROPLEX 600, Prothromplex, Prothromplex 600, Prothromplex 600 IE, Prothromplex 600 SV, Prothromplex 600 TV, Prothromplex 600 UI, Prothromplex NF 600, PROPLEX, Feiba, Prothromplex TOTAL | United States | Hemophilia B; Hemophilia A | Baxalta Incorporated | 1979-12-21 | Blood Coagulation Disorders; Blood Coagulation Disorders, Inherited; Hemophilia A; Hemophilia B; Cardiovascular Diseases | Details | |
| Apixaban | BMS-562247-01; BMS-562247; TAH-3311 | Approved | Bristol-Myers Squibb Company | Eliquis, 艾乐妥, 艾乐通 | EU | Venous Thromboembolism | Bristol-Myers Squibb/Pfizer Eeig | 2011-05-18 | Thrombocytopenia; Atrial Fibrillation; Ischemic Attack, Transient; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Aortic Valve Insufficiency; Astrocytoma; Primary Myelofibrosis; Colitis, Ulcerative; Ischemic Stroke; Colonic Diseases; Genital Neoplasms, Female; Lymphoma; Hemorrhage; Venous Thrombosis; Aortic Valve Stenosis; Nephrotic Syndrome; Thrombosis; Kidney Failure, Chronic; Thrombocythemia, Essential; Rectal Diseases; Crohn Disease; Fasting; Anemia, Sickle Cell; Pancreatic Neoplasms; Pulmonary Embolism; Embolism; Hematologic Neoplasms; Solid tumours; Venous Thromboembolism; Spinal Cord Injuries; Inflammatory Bowel Diseases; Polycythemia Vera; Cerebral Hemorrhage; Foramen Ovale, Patent; Atrial Flutter; Bone Marrow Neoplasms; Aortic valve diseases; Myeloproliferative Disorders; Glioblastoma; Neoplasms; Coronavirus Disease 2019 (COVID-19); Proteinuria; Acute Coronary Syndrome; Stroke; Thromboembolism; Glomerulonephritis, Membranous | Details |
| Turoctocog alfa | NNC0155-0000-0004; NN-7008 | Approved | Novo Nordisk A/S | Zonovate, Novoeight | United States | Hemophilia A | null | 2013-10-15 | Hemophilia A; Hemorrhage | Details |
| Human prothrombin complex (Nanyue Biopharming) | Approved | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | 2019-09-05 | Hemophilia B; Hemorrhage | Details | ||
| Human Antithrombin III (Hemarus Therapeutics) | Approved | Hemarus Therapeutics | India | Antithrombin III Deficiency | Hemarus Therapeutics | 2015-08-01 | Antithrombin III Deficiency | Details | ||
| Enoxaparin sodium biosimilar (Techdow) | Approved | Shenzhen Techdow Pharmaceutical Co Ltd | Inhixa | Mainland China | Embolism and Thrombosis | Shenzhen Techdow Pharmaceutical Co Ltd | 2005-08-18 | Pulmonary Embolism; Blood Coagulation Disorders; Venous Thromboembolism; Angina, Unstable; Coronavirus Disease 2019 (COVID-19); Embolism and Thrombosis; Coronavirus Infections; Pneumonia, Viral; Venous Thrombosis; Non-ST Elevated Myocardial Infarction | Details | |
| Moroctocog alfa | PF-05208756; r-VIII SQ; PF-5208756; r-Factor VIII SQ; BDDrFVIII | Approved | Pfizer Inc | ReFacto, Xyntha, Refacto AF, Xyntha Solofuse, Refacto AF/Xyntha, 任捷 | EU | Hemophilia A | Pfizer Europe Ma Eeig | 1999-04-13 | Hemophilia A | Details |
| Heparin sodium biosimilar (Chandra Bhagat Pharma) | Approved | Chandra Bhagat Pharma（Cbc） | Thromboparin | India | Thrombosis | Chandra Bhagat Pharma（Cbc） | 2012-08-01 | Thrombosis | Details | |
| Factor VIII (Tonrol Biopharmaceuticals) | Hemorass | Approved | Tonrol Bio-Pharmaceutical Co Ltd | HEMORAAS | Hemophilia A | Details | ||||
| Danaparoid sodium | KB-101; Org-10172 | Approved | Merck Sharp & Dohme Corp, Organon | Orgaran, Lomoparan | Netherlands | Thrombocytopenia; Venous Thromboembolism | null | 1991-01-01 | Venous Thromboembolism; Thrombocytopenia; Venous Thrombosis | Details |
| Eptacog alfa (Novo Nordisk) | NN-007 | Approved | Novo Nordisk A/S | NiaStase, NovoSeven, 诺其 | EU | Thrombasthenia; Factor VII Deficiency; Hemophilia A; Hemophilia B | Novo Nordisk A/S | 1996-02-23 | Cerebral Hemorrhage; Spinal Diseases; Hemophilia A; Hemophilia B; Liver Cirrhosis; Hemorrhage; Stroke; Postpartum Hemorrhage; Factor VII Deficiency; Severe Dengue; Burns; Blood Loss, Surgical; Wounds and Injuries; Thrombasthenia; Acquired hemophilia | Details |
| Human prothrombin complex (CSL Behring) | BE-1116 | Approved | Csl Behring Llc | Kcentra, Beriplex, Confidex | Japan | Vitamin K Deficiency Bleeding | Csl Behring Kk | Coagulation Protein Disorders; Blood Coagulation Disorders; Vitamin K Deficiency Bleeding; Heart Failure; Heart Diseases; Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Wounds and Injuries | Details | |
| Freeze-dried activated human blood coagulation factor Ⅶ concentrate containing factor Ⅹ (Kaketsuken/KM Biologics) | MC-710 | Approved | Byclot | Japan | Hemophilia A | null | 2014-07-04 | Hemophilia A | Details | |
| Trenonacog alfa | IB-1001; APVO-101 | Approved | Inspiration Biopharmaceuticals | Ixinity | United States | Hemophilia B | null | 2015-05-14 | Hemophilia B | Details |
| Human prothrombin complex concentrate (Guizhou Taibang Biological Products) | Approved | Guizhou Taibang Biological Products Co Ltd | Mainland China | Hypoprothrombinemias | Guizhou Taibang Biological Products Co Ltd | 2013-07-31 | Hypoprothrombinemias | Details | ||
| Factor VIII (CSL) | Approved | Csl Ltd | Beriate | Sweden | Hemophilia A | Csl Behring Gmbh | 1997-06-06 | Hemophilia A | Details | |
| Enoxaparin sodium biosimilar (PT Kalbe) | Approved | Kalbe Farma | Kalbenox | Cambodia | Myocardial Infarction; Venous Thrombosis; Angina, Unstable | Kalbe Farma | 2012-01-01 | Myocardial Infarction; Angina, Unstable; Venous Thrombosis | Details | |
| Rivaroxaban | JNJ-39039039; BAY-59-7939; YHP-1807; YHR-1901 | Approved | Bayer AG, Johnson & Johnson Pharmaceutical Research & Development LLC | Xarelto, 拜瑞妥 | Canada | Atherosclerosis | Bayer AG | 2008-09-15 | Intraoperative Complications; Coronary Disease; Atrial Fibrillation; Breast Feeding; Osteoarthritis, Knee; Rheumatic Heart Disease; Rheumatic Diseases; Cardiovascular Diseases; Urologic Neoplasms; Venous Thrombosis; Thrombocytopenia; Arthritis; Antiphospholipid Syndrome; Renal Insufficiency, Chronic; Postoperative Complications; Obesity; Breast Milk Expression; Thrombosis; Heart Defects, Congenital; Peripheral Arterial Disease; Osteoarthritis, Hip; Anemia, Sickle Cell; Respiratory Insufficiency; Kidney Failure, Chronic; Arterial Occlusive Diseases; Myocardial Ischemia; Embolism; Upper Extremity Deep Vein Thrombosis; Heart Failure; Angina, Unstable; Venous Thromboembolism; Myocardial Infarction; Mitral Valve Stenosis; Atherosclerosis; Diabetes Mellitus, Type 2; Communicable Diseases; Pulmonary Embolism; Coronary Artery Disease; Coronavirus Disease 2019 (COVID-19); Neoplasms; Obesity, Morbid; beta-Thalassemia; Thromboembolism; Stroke; Acute Coronary Syndrome; Embolism and Thrombosis; Puerperal Disorders; Hemorr | Details |
| Human Coagulation Factor Ⅷ (Hualan Biological Engineering) | Approved | Hualan Genetic Engineering Co Ltd | 康斯平, Kangsiping | Mainland China | Blood Coagulation Disorders; Hemophilia A | Hualan Biological Engineering Inc | 2000-01-01 | Blood Coagulation Disorders; Hemophilia A | Details | |
| Antithrombin III (Human, Grifols) | Approved | Grifols Sa | Thrombate III | United States | Thromboembolism; Antithrombin III Deficiency | null | 1991-12-30 | Venous Thromboembolism; Coronavirus Disease 2019 (COVID-19); Liver Cirrhosis; Heart Diseases; Thromboembolism; Antithrombin III Deficiency; Wounds and Injuries; Postoperative Complications; Venous Thrombosis | Details | |
| Susoctocog alfa | BAX-801; OBI-1; TAK-672; SHP-672; BAX-802 | Approved | Baxalta Incorporated | Obizur | United States | Hemophilia A | null | 2014-10-23 | Hemophilia A; Hemorrhage; Acquired hemophilia | Details |
| Enoxaparin sodium biosimilar (Neiss Labs) | Approved | Neiss Labs | Lomonox | India | Venous Thrombosis | Neiss Labs | 2012-08-01 | Venous Thrombosis | Details | |
| Certoparin sodium | Approved | Novartis Pharma Ag | Troparin, Alphaparin, Sandoparin, Sandoparine, Mono-Embolex | Pulmonary Embolism; Thromboembolism; Venous Thrombosis | null | 1997-01-01 | Embolism; Pulmonary Embolism; Renal Insufficiency; Kidney Diseases; Thromboembolism; Atrial Fibrillation; Venous Thrombosis | Details | ||
| Parnaparin sodium | OP-2123; CB-01-05 | Approved | Opocrin Spa, Alfasigma Spa | Fluxum, Lowhepa, Minidalton | Italy | Thrombosis | null | 1993-01-01 | Thrombophlebitis; Infertility; Thrombosis | Details |
| Octocog alfa | BAY14-2222 | Approved | Bayer AG | Kogenate, Helixate NexGen, Kovaltry, Iblias, Kogenate/Kovaltry, 科跃奇 | United States | Hemophilia A | Bayer Healthcare | 1993-02-25 | Blood Coagulation Disorders; Hemophilia A | Details |
| Moroctocog alfa biosimilar (International Biotech Center Generium) | GNR-002 | Approved | International Biotech Center Generium | Octofactor | Russian Federation | Hemophilia A | International Biotech Center Generium | 2013-01-01 | Hemophilia A | Details |
| Antihemophilic factor/von Willebrand factor (CSL Behring) | Approved | Csl Behring Llc | Aleviate, Voncento, Humate-P, Biostate, Haemate P | United States | von Willebrand Diseases; Hemophilia A | null | 1999-04-01 | von Willebrand Diseases; Hemophilia A | Details | |
| Antihemophilic factor B (Armour) | Approved | Csl Behring Llc, Armour Pharma | MonoFIX, Mononine | Hemophilia B | null | 1993-05-01 | Hemophilia B | Details | ||
| Ardeparin sodium | Approved | Wyeth-Ayerst | Normiflo | United States | Pulmonary Embolism; Venous Thrombosis | null | 1997-05-01 | Pulmonary Embolism; Venous Thrombosis | Details | |
| Dalteparin Sodium | FR-860; KV-165; KABI-2165 | Approved | Pfizer Inc | 法安明, Fragmin | Germany | Thrombosis | Pfizer Inc | 1985-01-01 | Puerperal Disorders; Thrombosis; Anemia, Sickle Cell; Thrombophilia; Venous Thrombosis; Lung Neoplasms; Pregnancy Complications; Colorectal Neoplasms; Parturition; Brain Neoplasms; Atrial Fibrillation; Hepatic Veno-Occlusive Disease; Prostatic Neoplasms; Breast Neoplasms; Diabetic Foot; Abortion, Habitual; Thromboembolism; Central Nervous System Neoplasms; Stroke; Coronary Artery Disease; Neoplasms; Renal Insufficiency; Angina, Unstable; Myocardial Infarction; Brain Injuries, Traumatic; Venous Thromboembolism; Ovarian Neoplasms; Pulmonary Embolism | Details |
| Turoctocog alfa pegol | NN-7088; N8-GP; N8-GP-rFVIII; NNC-0129-0000-1003 | Approved | Novo Nordisk A/S | Esperoct | United States | Hemophilia A | Novo Nordisk Inc | 2019-02-19 | Hemophilia A; Hemorrhage | Details |
| NecLip-pdFVIII | pdFVIII | Approved | Recoly Nv | LongAte, LongEight | Hemophilia A | Details | ||||
| Prothrombinex-VF (CSL Behring) | Approved | Csl Behring Llc | Australia | Hemorrhage | Csl Behring Llc | 2014-10-01 | Hemorrhage | Details | ||
| Factor VIII (Shanxi Kangbao Biological Products) | Approved | Shanxi Kangbao Biological Product Co Ltd | Mainland China | Hemophilia A | Shanxi Kangbao Biological Product Co Ltd | 2020-08-14 | Hemophilia A | Details | ||
| Factor VIII biosimilar (Chia Tai-Tianqing) | KN-008 | Approved | Suzhou Alphamab Co Ltd | 安恒吉 | Mainland China | Hemophilia A | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-08-29 | Hemophilia A | Details |
| Recombinant Human Coagulation Factor VIII (sinocelltech) | SCT-800 | Approved | SinoCelltech Ltd | Mainland China | Hemophilia A | SinoCelltech Ltd | 2021-07-20 | Hemophilia A; Blood Loss, Surgical | Details | |
| Efmoroctocog alfa | BIIB-031; rFVIIIFc | Approved | Biogen Inc, Sobi, Bioverativ Inc | Elocta, Eloctate | United States | Hemophilia A | null | 2014-06-06 | Hemophilia A | Details |
| Efanesoctocog alfa | BIVV-001; BIVV001 | Approved | Amunix Pharmaceuticals Inc | Altuviiio | United States | Hemophilia A | Sanofi | 2023-02-23 | von Willebrand Diseases; Hemophilia A | Details |
| Lonoctocog alfa | CSL-627; NBP-601 | Approved | Sk Chemicals, Csl Behring Llc | Afstyla | United States | Hemophilia A | Csl Behring Ag | 2016-05-25 | Hemophilia A | Details |
| Antihemophilic Factor (Recombinant) | Approved | Recombinate | United States | Hemophilia A | null | 1992-12-10 | Hemophilia A | Details | ||
| Prothrombin complex concentrate (Sanquin) | Approved | Sanquin Plasma Products Bv | Cofact | Hemorrhage | Sanquin Plasma Products Bv | 2007-11-01 | Hemorrhage | Details | ||
| Enoxaparin sodium biosimilar (Rovi) | Approved | Rovi | Arovi | Angina, Unstable; Myocardial Infarction; Venous Thrombosis | Rovi | 2018-03-31 | Angina, Unstable; Myocardial Infarction; Venous Thrombosis | Details | ||
| Emicizumab | RG-6013; ACE-910; RO-5534262 | Approved | Genentech Inc, Chugai Pharmaceutical Co Ltd | 舒友立乐, Hemlibra | United States | Hemophilia A | Genentech Inc | 2017-11-16 | Hemophilia A; Hemorrhage; von Willebrand Disease, Type 3 | Details |
| Human Coagulation Factor IX (Hemarus Therapeutics) | Approved | Hemarus Therapeutics | Clotnine | India | Hemophilia B | Hemarus Therapeutics | 2015-08-01 | Hemophilia B | Details | |
| Human Coagulation Factors IX and X (CSL Behring) | Approved | Csl Behring Llc | Factor X P Behring | Hemophilia B | Details | |||||
| Enoxaparin sodium biosimilar (Blau Pharmaceuticals) | Approved | Blau Pharmaceuticals | Enoxalow | Thrombosis | Blau Pharmaceuticals | 2013-07-01 | Thrombosis | Details | ||
| Nonacog alfa | rh-F-IX; rh-Factor-IX | Approved | Pfizer Inc | 贝赋, BeneFIX | EU | Hemophilia B | Pfizer Europe Ma Eeig | 1997-08-27 | Hemophilia B | Details |
| Eptacog alfa biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Iran | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Aryogen Biopharma | 2014-01-01 | Hemophilia A; Hemophilia B; Factor VII Deficiency; Thrombasthenia | Details | ||
| Nonacog alfa (International Biotech Center Generium) | GNR-003 | Approved | International Biotech Center Generium | Innonafactor | Russian Federation | Hemophilia B | International Biotech Center Generium | 2014-01-01 | Hemophilia B | Details |
| Factor IX complex (Grifols) | Approved | Grifols Sa | Profilnine | United States | Hemophilia B | null | 1981-07-21 | Intracranial Hemorrhages; Hemophilia B | Details | |
| Edoxaban Tosilate Hydrate | DU-176b | Approved | Daiichi Sankyo Co Ltd | Savaysa, 里先安, Roteas, Lixiana, Lixiana/Savaysa | Japan | Pulmonary Embolism; Embolism; Stroke; Venous Thromboembolism; Venous Thrombosis | Daiichi Sankyo Co Ltd | 2011-04-22 | Embolism and Thrombosis; Thrombosis; Obesity; Inflammation; Aortic Valve Stenosis; Venous Thrombosis; Osteoarthritis, Knee; Ischemic Stroke; Atrial Fibrillation; Pulmonary Embolism; Stroke; Thromboembolism; Neoplasms; Heart Diseases; Venous Thromboembolism; HIV Infections; Embolism | Details |
| Nonacog beta pegol | N9-GP; NN-7999; 40K-PEG-rFIX; NNC-0156-0000-0009 | Approved | Novo Nordisk A/S | Rebinyn, Refixia | United States | Hemophilia B | Novo Nordisk Inc | 2017-05-31 | Hemophilia B; Hemorrhage | Details |
| Human coagulation factor VIII (Green Cross Biological Products) | Approved | Mainland China | Blood Coagulation Disorders | Green Cross China Biological Products Co Ltd | 2000-01-01 | Blood Coagulation Disorders | Details | |||
| Enoxaparin sodium biosimilar (Harvest Moon Pharmaceuticals) | Approved | Harvest Moon | Angina, Unstable; Myocardial Infarction; Venous Thromboembolism; Venous Thrombosis | Details | ||||||
| Eptacog beta | LR-769; rhFVIIa | Approved | Lfb Biotechnologies Sas, Revo Biologics Inc | Sevenfact | United States | Hemophilia A; Hemophilia B | Lfb Biotechnologies Sas | 2020-04-01 | Hemophilia A; Hemophilia B | Details |
| Simoctocog alfa | Factor VIII; Human-cl rhFVIII | Approved | Octapharma | Vihuma, Nuwiq | EU | Hemophilia A | Octapharma Ab | 2014-07-22 | Hemophilia A | Details |
| Human prothrombin complex (Octapharma) | Approved | Octapharma | Ocplex, Octaplex, Pronativ | Germany | Hemorrhage | Octapharma | 2003-03-14 | Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Nonacog gamma | rFIX; BAX-326 | Approved | Rixubis | United States | Hemophilia B | null | 2013-06-26 | Hemophilia B | Details | |
| Factor VIII/von Willebrand factor (Bio Products Laboratory) | Approved | Bio Products Laboratory Ltd | Optivate | Hemophilia A | Bio Products Laboratory Ltd | 2004-12-01 | von Willebrand Diseases; Hemophilia A | Details | ||
| Eptacog alfa biosimilar (International Biotech Center Generium) | GNR-001 | Approved | International Biotech Center Generium | Russian Federation | Hemophilia A | International Biotech Center Generium | 2015-01-01 | Hemophilia A | Details | |
| Antihemophilic factor/von Willebrand factor complex (Human, Grifols Biologicals) | Approved | Grifols Sa | Alphanate | United States | Hemophilia A; von Willebrand Diseases | null | 1978-08-15 | von Willebrand Diseases; Hemophilia A | Details | |
| Rurioctocog alfa pegol | BAX-0855; BAX-855; TAK-660 | Approved | Baxalta Incorporated, Nektar Therapeutics | Adynovi, Adynovate | United States | Hemophilia A | null | 2015-11-13 | Hemophilia A | Details |
| Human prothrombin complex (LFB) | Approved | Lfb Biotechnologies Sas | KANOKAD | France | Hemorrhage | Lfb Biotechnologies Sas | 2008-09-01 | Hemorrhage | Details | |
| Eftrenonacog Alfa | BIIB-029; FIX:Fc; FIXFc; rFIXFc | Approved | Sobi, Biogen Inc, Bioverativ Inc | Alprolix, 赛玖凝 | United States | Hemophilia B | null | 2014-03-28 | Hemophilia B | Details |
| Factor VIII (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Factocel VIII | Hemophilia A | Details | |||||
| Moroctocog alfa biosimilar (Amega Biotech) | Approved | Amega Biotech | Argentina | Hemophilia A | Amega Biotech | 2012-01-01 | Hemophilia A | Details | ||
| Fondaparinux Sodium | GSK-576428; Org-31540; SR-90107; SR-90107A | Approved | Organon | Arixtra, Quixidar, 安卓 | United States | Venous Thrombosis; Liver Diseases; Pulmonary Embolism | Mylan Ireland Ltd | 2001-12-07 | Angina Pectoris; Uterine Cervical Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Venous Thrombosis; Sarcoma; Vulvar Neoplasms; Atrial Fibrillation; Coronary Disease; Liver Diseases; Pulmonary Embolism; Thromboembolism; Obesity, Morbid; Neoplasms; Vaginal Neoplasms; Renal Insufficiency; Venous Thromboembolism; Angina, Unstable; Myocardial Infarction; Ovarian Neoplasms | Details |
| Enoxaparin sodium biosimilar (Chandra Bhagat Pharma) | Approved | Chandra Bhagat Pharma（Cbc） | MAXIPARINE | Venous Thrombosis | Details | |||||
| Antithrombin III (CSL Behring) | BI51.017 | Approved | Csl Behring Llc | Kybernin, Anthrobin, Athimbin | Japan | Thrombosis; Disseminated Intravascular Coagulation | Csl Behring Llc | 1987-08-02 | Disseminated Intravascular Coagulation; Thrombosis | Details |
| Heparin sodium biosimilar (Blau Pharmaceuticals) | Approved | Blau Pharmaceuticals | Hepamax-S | Brazil | Thrombosis | Blau Pharmaceuticals | 2012-08-01 | Thrombosis | Details | |
| Human prothrombin complex (Tonrol Biopharmaceuticals) | Approved | Tonrol Bio-Pharmaceutical Co Ltd | ProthoRAAS | Mainland China | Hemorrhage | Shanghai Raas Blood Products Co Ltd | 1996-01-01 | Hemophilia B; Hemorrhage | Details | |
| Human Coagulation Factor VIII (Hemarus Therapeutics) | Approved | Hemarus Therapeutics | CLOTATE | India | Hemophilia A | Hemarus Therapeutics | 2015-08-01 | Hemophilia A | Details | |
| Human factor IX (LFB) | Approved | Lfb Biotechnologies Sas | Betafact | Netherlands | Hemophilia B | Lfb Biotechnologies Sas | 2000-05-01 | Hemophilia B | Details | |
| Albutrepenonacog alfa | CSL-640; CSL-654 | Approved | Csl Behring Llc | Idelvion | United States | Hemophilia B | null | 2016-03-04 | Hemophilia B | Details |
| Enoxaparin sodium biosimilar (Fresenius Kabi) | Approved | Fresenius Kabi Canada Ltd | ELONOX, ELONOX HP | Canada | Thromboembolism; Venous Thrombosis | Fresenius Kabi Canada Ltd | 2022-10-26 | Thromboembolism; Venous Thrombosis | Details | |
| Recombinant Human Coagulation Factor Ⅷ (Chengdu Rongsheng Pharmaceuticals) | Approved | Chengdu Rongsheng Pharmaceuticals Co Ltd | Mainland China | Hemophilia A | Chengdu Rongsheng Pharmaceuticals Co Ltd | 2023-09-05 | Hemophilia A | Details | ||
| Human prothrombin complex (ShenzhenWeiguang Biological Products) | Approved | Shenzhen Weiguang Biological Products Co Ltd | Mainland China | Hemorrhage | Shenzhen Weiguang Biological Products Co Ltd | 2024-05-21 | Hemophilia B; Hemorrhage | Details | ||
| Human prothrombin complex (Guangdong Shuanglin) | Approved | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia B | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | 2023-05-12 | Hemophilia B | Details | ||
| Human coagulation factor Ⅷ (Shanghai Xinxing) | Approved | Shanghai Xinxing Medicine Co Ltd | Mainland China | Hemophilia A; Hemorrhagic Disorders | Shanghai Xinxing Medicine Co Ltd | 2015-07-27 | Hemorrhagic Disorders; Hemophilia A | Details | ||
| Human coagulation factor Ⅷ (Shanghai Institute of Biological Products) | Approved | Mainland China | Hemorrhagic Disorders; Hemophilia A | Shanghai Institute Of Biological Products Co Ltd | 2012-07-23 | Hemorrhagic Disorders; Hemophilia A | Details | |||
| Human coagulation factor Ⅷ (Shandong Taibang) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Shandong Taibang Biological Products Co Ltd | 2012-06-15 | Details | ||||
| Human Coagulation Factor Ⅷ (Sinopharm Shanghai Plasma) | Approved | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | Mainland China | Hemophilia A | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | 2012-07-23 | Hemophilia A | Details | ||
| Human prothrombin complex (Shanghai Xinxing) | Approved | Shanghai Xinxing Medicine Co Ltd | Mainland China | Hemorrhage | Shanghai Xinxing Medicine Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
| Human prothrombin complex (Sinopharm Shanghai Plasma) | Approved | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | Mainland China | Hemorrhage | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
| Human prothrombin complex (Boya Bio-Pharmaceutical) | Approved | Boya Bio-Pharmaceutical Group Co Ltd | Mainland China | Hemorrhage | Boya Bio-Pharmaceutical Group Co Ltd | 2020-12-02 | Hemophilia B; Hemorrhage | Details | ||
| Human prothrombin complex (Guangdong Wellen) | Approved | Guangdong Wellen Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Guangdong Wellen Pharmaceutical Co Ltd | 2020-10-21 | Hemophilia B; Hemorrhage | Details | ||
| Human Coagulation Factor Ⅷ (Shanghai Raas Blood Products) | Approved | Shanghai Raas Blood Products Co Ltd | Mainland China | Hemophilia A | Shanghai Raas Blood Products Co Ltd | 1995-01-01 | Hemophilia A | Details | ||
| Factor IX (Bio Products Laboratory) | Approved | Bio Products Laboratory Ltd | Replenine-VF | United Kingdom | Hemophilia B | Bio Products Laboratory Ltd | 1999-08-09 | Hemophilia B | Details | |
| Human prothrombin complex (Lanzhou Lansheng Blood Products) | Approved | Lanzhou Lansheng Blood Products Co Ltd | Mainland China | Hemophilia B | Lanzhou Lansheng Blood Products Co Ltd | 2024-09-26 | Hemophilia B | Details | ||
| Human Coagulation Factor Ⅷ（Tonrol Bio-Pharmaceutical ） | Approved | Tonrol Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia A | Tonrol Bio-Pharmaceutical Co Ltd | 2013-08-23 | Hemophilia A | Details | ||
| Antithrombin III (Octapharma Ab) | Approved | Octapharma Ab | Atenativ | EU | Antithrombin III Deficiency | Octapharma Ab | 2007-12-20 | Antithrombin III Deficiency | Details | |
| Human prothrombin complex(Hebei Daan Pharmaceutical) | Approved | Hebei Daan Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hebei Daan Pharmaceutical Co Ltd | 2020-01-01 | Hemophilia B; Hemorrhage | Details | ||
| Human Coagulation Factor Ⅷ (Jiangxi Boya Bio-Pharmaceutical ) | Approved | Boya Bio-Pharmaceutical Group Co Ltd | Mainland China | Hemophilia A | Boya Bio-Pharmaceutical Group Co Ltd | 2022-08-08 | Hemophilia A; Hemorrhage | Details | ||
| Human Coagulation Factor Ⅷ (Guangdong Shuanglin Bio-Pharmaceutical) | Approved | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia A | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | 2020-06-17 | Hemophilia A | Details | ||
| Human coagulation factor Ⅷ (Shenzhen Weiguang Biological Products) | Approved | Shenzhen Weiguang Biological Products Co Ltd | Mainland China | Hemophilia A | Shenzhen Weiguang Biological Products Co Ltd | 2023-10-27 | Hemophilia A | Details | ||
| Polysulfonic mucopolysaccharide | M-118102; M-1180B; M-7040B | Approved | Maruho Co Ltd | 喜辽妥, 喜疗妥 | Japan | Thrombophlebitis; Arthritis; Cicatrix; Chilblains | Maruho Co Ltd | 1954-10-01 | Phlebitis; Thrombophlebitis; Cicatrix; Chilblains; Contusions; Arthritis | Details |
| Human coagulation factor VIII(Biotest Pharma Gmbh) | Approved | Biotest Pharma Gmbh | Haemoctin SDH | Hemophilia A | Details | |||||
| Human Coagulation Factor IX(China Biologic Products) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Hemophilia B | Shandong Taibang Biological Products Co Ltd | 2020-07-08 | Hemophilia B | Details | ||
| Factor IX (Sichuan Yuanda Shuyang Pharmaceutical) | Approved | Yuanda Shuyang Life Sciences (Chengdu) Co Ltd | Mainland China | Hemophilia B | Yuanda Shuyang Life Sciences (Chengdu) Co Ltd | 2023-02-14 | Hemophilia B; Hemorrhage | Details | ||
| Prothrombin complex concentrat (Taibang Biological Products) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Hemorrhage | Shandong Taibang Biological Products Co Ltd | 2014-09-30 | Antithrombin III Deficiency; Hemorrhage | Details | ||
| Human prothrombin complex (Hualan Biological Engineering) | Approved | Hualan Genetic Engineering Co Ltd | Mainland China | Factor X Deficiency; Blood Coagulation Disorders | Hualan Biological Engineering Inc | 1999-01-01 | Blood Coagulation Disorders; Hemophilia B; Factor X Deficiency | Details | ||
| Enoxaparin sodium biosimilar (Sahar International Trading) | Approved | Sahar International Trading | Angina, Unstable; ST Elevation Myocardial Infarction; Venous Thromboembolism; Blood Coagulation Disorders | Sahar International Trading | 2013-07-01 | Blood Coagulation Disorders; Angina, Unstable; ST Elevation Myocardial Infarction; Venous Thromboembolism | Details | |||
| Human prothrombin complex concentrate (Shanxi Kangbao Biological Products) | Approved | Shanxi Kangbao Biological Product Co Ltd | Mainland China | Hemorrhage | Shanxi Kangbao Biological Product Co Ltd | 2019-09-17 | Hemophilia B; Hemorrhage | Details | ||
| Beroctocog alfa | GC-1101; GC-1101C; GC1101D | Approved | GC Biopharma Corp | GreenGene F, 绿茵芷 | South Korea | Hemophilia A | GC Biopharma Corp | 2009-12-01 | Hemophilia A | Details |
| Damoctocog alfa pegol | BAY-949027 | Approved | Bayer AG | Jivi | United States | Hemophilia A | Bayer Healthcare | 2018-08-29 | Hemophilia A; Hemorrhage | Details |
- Molekülinformation
- Produktanfrage
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main